PNC Managed Account Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

PNC Managed Account Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$22K	Buy	+260	New	+$20.6K	﹤0.01%	426

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PNC Managed Account Solutions's BMRN Position: Q2 2021 in Review

PNC Managed Account Solutions opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2021: 260 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #426 among its holdings.

529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

PNC Managed Account Solutions held 260 shares of BioMarin Pharmaceuticals worth $22K as of Q2 2021.
BioMarin Pharmaceuticals was a new PNC Managed Account Solutions position in Q2 2021.
BioMarin Pharmaceuticals made up ﹤0.01% of PNC Managed Account Solutions's portfolio in Q2 2021, its #426 holding.
529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on PNC Managed Account Solutions's 13F filing for Q2 2021, filed 6 Aug 2021.